Login
Neos Therapeutics NASDAQ: NEOS
Neos Therapeutics is focused on developing, manufacturing, and commercializing innovative extended-release products that utilize our proprietary modified-release drug delivery technology platform
| Name | Neos Therapeutics |
| Ticker | NEOS |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Drug Manufacturers -Specialty Pharma |
|
Price
52W Low/High |
1.15
0.47 / 1.26 |
| Momentum | Weak Up |
| Market cap | 57 M |
| 1Y Total Return |
19.92%
Weak |
| 1Y Volatility |
99.63%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Neos Therapeutics is focused on developing, manufacturing, and commercializing innovative extended-release products that utilize our proprietary modified-release drug delivery technology platform
Details
| Ticker | NEOS |
| Name | Neos Therapeutics |
| ISIN | US64052L1061 |
| CUSIP | |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Drug Manufacturers -Specialty Pharma |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 3/19/21
| Close Price | 1.15 |
| 52W Low/High | 0.47 / 1.26 |
| Market cap | 57 M |
| 1Y Total Return |
19.92%
Weak |
| 1Y Volatility |
99.63%
High Risk |
| Beta | 2.41 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -38.4% |
| Cash from Op. / Cur. Liabilities | -0.10 |
| Diluted Earnings / Share | -0.44 |
| ROE | - |
| ROIC | - |
| Price / Revenue | 1.0 |
| Price / Book | -2.8 |
| Price / CF | -8.9 |
| Current Ratio | 0.7 |
| Cur.Liabilities / Tot.Liabilities | 0.8 |
| Financial Leverage | - |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
57
|
63
|
44
|
22
|
7
|
3
|
|
| Gross Profit |
32
|
38
|
21
|
8
|
-
|
-
|
|
| R&D |
6
|
9
|
8
|
11
|
11
|
11
|
|
| EBITDA |
-10
|
-11
|
-43
|
-58
|
-65
|
-20
|
|
| Operating Income |
-13
|
-16
|
-47
|
-62
|
-68
|
-22
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
50
|
50
|
30
|
28
|
16
|
12
|
|
| EPS exc. Extra |
-0.44
|
-0.42
|
-1.88
|
-3.39
|
-3.38
|
-23.52
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
65
|
92
|
73
|
113
|
97
|
131
|
|
| Cash, Eq & Invt ShortTerm |
13
|
25
|
17
|
66
|
60
|
103
|
|
| Total Current Assets |
44
|
68
|
50
|
88
|
72
|
106
|
|
| Total Non-Current Assets |
21
|
24
|
23
|
25
|
25
|
25
|
|
| Intangibles |
11
|
13
|
15
|
17
|
16
|
17
|
|
| Total Liabilities |
85
|
95
|
100
|
98
|
82
|
44
|
|
| Total Current Liabilities |
67
|
61
|
53
|
36
|
21
|
13
|
|
| Long Term Debt |
18
|
34
|
46
|
62
|
60
|
31
|
|
| Shareholder equity |
-21
|
-3
|
-27
|
15
|
16
|
87
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-6
|
-17
|
-51
|
-58
|
-62
|
-19
|
|
| Depreciation |
4
|
4
|
3
|
3
|
3
|
3
|
|
| Cash from Investing |
1
|
-3
|
22
|
-6
|
-21
|
2
|
|
| Capex |
1
|
1
|
1
|
3
|
4
|
1
|
|
| Cash from Financing |
-6
|
27
|
3
|
64
|
23
|
109
|
|
| Stock Issued |
0
|
43
|
4
|
65
|
0
|
101
|
|
| Debt (LT) Issued |
-6
|
-16
|
-1
|
-1
|
23
|
8
|
|
| Free Cash Flow |
9
|
-16
|
-22
|
-63
|
-85
|
-
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
0.7
|
1.1
|
0.9
|
2.4
|
3.4
|
8.0
|
|
| Financial Leverage D/E |
-
|
-
|
-
|
4.48
|
3.88
|
0.39
|
|
| Return on Capital Avg |
-
|
-274.3%
|
-253.3%
|
-183.4%
|
-287.5%
|
-314.2%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available